Vera Therapeutics Reaches FDA Agreement, Accelerating Approval Timeline for Atacicept in IgA Nephropathy
Vera Therapeutics (NASDAQ:VERA) announced an agreement with the U.S. Food and Drug Administration to accelerate its regulatory timeline for atacicept, a potential treatment for adult patients with IgA nephropathy. The company plans to release eGFR findings in Q3 2026 and file a supplemental Biologics License Application by year-end.
Tickers: $VERA
Topics: biotech clinical_trials drug_approval